Next 10 |
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
2024-07-11 09:02:04 ET Clene Inc (CLNN) announced stock split at a ratio of 1-for-20 on 2024-07-11 ... Full story available on KlickAnalytics.com
SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal fu...
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today anno...
2024-07-09 08:22:48 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene to effect 1-for-20 reverse s...
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal fu...
Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in ...
Currently, more than 10 million individuals are affected by Parkinson’s disease around the world. This degenerative condition affects an individual’s nervous system and damages parts of the brain that control movement, causing involuntary shaking and stiff muscles as well as bal...
Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,...
News, Short Squeeze, Breakout and More Instantly...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
2024-07-11 09:02:04 ET Clene Inc (CLNN) announced stock split at a ratio of 1-for-20 on 2024-07-11 ... Full story available on KlickAnalytics.com